Literature DB >> 24368159

Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the α-L-iduronidase gene in Hurler-Scheie syndrome.

Alia Ahmed1, Chester B Whitley1, Renee Cooksley1, Kyle Rudser2, Stephanie Cagle3, Nadia Ali3, Kathleen Delaney1, Brianna Yund1, Elsa Shapiro1.   

Abstract

UNLABELLED: The lysosomal enzyme α-L-iduronidase hydrolyzes terminal iduronic acid from heparan sulfate and dermatan sulfate, and is an essential step in GAG degradation. Mutations of its gene, IDUA, yield a spectrum of mucopolysaccharidosis (MPS) type I clinical disorders. The IDUA mutation, c.712T>A (p.L238Q) was previously noted as a mild mutation. In a longitudinal study of MPS brain structure and function (Lysosomal Disease Network), we found this mutation in 6 of 14 Hurler-Scheie syndrome patients in the age range of 15 to 25 years. We hypothesized that L238Q, when paired with a nonsense mutation, is significantly more severe than other missense-nonsense combinations.
METHODS: Of 6 patients with a L238Q mutation, the L238Q allele was paired with a nonsense mutation in 4 patients, paired with a deletion in 1, and with a splice site mutation in another. This group was compared to 6 Hurler-Scheie patients closely matched in age and mutation type. IQ and other neuropsychological tests were administered as part of the protocol. Medical history was compiled into a Physical Symptom Score (PSS). Assessment of IQ, attention, memory, spatial ability, adaptive function and psychological status were measured.
RESULTS: No group differences were found in mean age at evaluation (17.8 and 19.0 years), duration of ERT, or PSS. By history, all were reported to be average in IQ (4/6 with documentation) in early childhood. All (100%) of the L238Q group had a psychiatric history and sleep problems compared to none (0%) of the comparison group. Significant differences were found in depression and withdrawal on parent report measures. IQ was lower in the L238Q group (mean IQ 74) than the comparison group (mean IQ 95; p<0.016). Attention, memory, and visual-spatial ability scores were also significantly lower. Three occurrences of shunted hydrocephalus, and 4 of cervical cord compression were found in the L238Q group; the comparison group had one occurrence of unshunted hydrocephalus and two of cord compression. DISCUSSION: The missense mutation L238Q, when paired with a nonsense mutation, is associated with significant, late-onset brain disease: psychiatric disorder, cognitive deficit, and general decline starting at a later age than in Hurler syndrome with a mutation-related rate of GAG accumulation and its pathologic sequelae. This particular genotype-phenotype may provide insight into the genesis of psychiatric illnesses more broadly. Consideration of methods for early, brain-targeted treatment in these patients might be considered.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hurler-Scheie syndrome; L238Q; Missense mutation; Mucopolysaccharidosis Type I; Nonsense mutation; α-L-iduronidase

Mesh:

Substances:

Year:  2013        PMID: 24368159      PMCID: PMC3939822          DOI: 10.1016/j.ymgme.2013.11.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  Identification and characterization of -3c-g acceptor splice site mutation in human alpha-L-iduronidase associated with mucopolysaccharidosis type IH/S.

Authors:  Y N Teng; T R Wang; W L Hwu; S P Lin; G J Lee-Chen
Journal:  Clin Genet       Date:  2000-02       Impact factor: 4.438

2.  Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations.

Authors:  C E Beesley; C A Meaney; G Greenland; V Adams; A Vellodi; E P Young; B G Winchester
Journal:  Hum Genet       Date:  2001-10-19       Impact factor: 4.132

3.  Structural and clinical implications of amino acid substitutions in α-L-iduronidase: insight into the basis of mucopolysaccharidosis type I.

Authors:  Seiji Saito; Kazuki Ohno; Nobuo Maita; Hitoshi Sakuraba
Journal:  Mol Genet Metab       Date:  2013-10-12       Impact factor: 4.797

4.  The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.

Authors:  Gregory M Pastores; Pamela Arn; Michael Beck; Joe T R Clarke; Nathalie Guffon; Paige Kaplan; Joseph Muenzer; Denise Y J Norato; Elsa Shapiro; Janet Thomas; David Viskochil; J Edmond Wraith
Journal:  Mol Genet Metab       Date:  2007-03-02       Impact factor: 4.797

5.  Regression-based pediatric norms for the brief visuospatial memory test: revised and the symbol digit modalities test.

Authors:  A M Smerbeck; J Parrish; E A Yeh; M Hoogs; Lauren B Krupp; B Weinstock-Guttman; R H B Benedict
Journal:  Clin Neuropsychol       Date:  2011-03-07       Impact factor: 3.535

6.  Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area.

Authors:  G Bach; S M Moskowitz; P T Tieu; A Matynia; E F Neufeld
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

7.  Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes.

Authors:  H S Scott; T Litjens; P V Nelson; P R Thompson; D A Brooks; J J Hopwood; C P Morris
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

Review 8.  Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

Authors:  H S Scott; S Bunge; A Gal; L A Clarke; C P Morris; J J Hopwood
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

9.  A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype.

Authors:  H S Scott; T Litjens; J J Hopwood; C P Morris
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

10.  Mutation analysis of 19 North American mucopolysaccharidosis type I patients: identification of two additional frequent mutations.

Authors:  L A Clarke; P V Nelson; C L Warrington; C P Morris; J J Hopwood; H S Scott
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

View more
  12 in total

1.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

2.  Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kyle Rudser; Kathleen Delaney; Victor Kovac; Alia Ahmed; Brianna Yund; Paul J Orchard; Julie Eisengart; Gregory R Niklason; Julian Raiman; Eva Mamak; Morton J Cowan; Mara Bailey-Olson; Paul Harmatz; Suma P Shankar; Stephanie Cagle; Nadia Ali; Robert D Steiner; Jeffrey Wozniak; Kelvin O Lim; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2015-06-17       Impact factor: 4.797

3.  Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.

Authors:  Brianna Yund; Kyle Rudser; Alia Ahmed; Victor Kovac; Igor Nestrasil; Julian Raiman; Eva Mamak; Paul Harmatz; Robert Steiner; Heather Lau; Pooja Vekaria; Jeffrey R Wozniak; Kelvin O Lim; Kathleen Delaney; Chester Whitley; Elsa G Shapiro
Journal:  Mol Genet Metab       Date:  2014-12-09       Impact factor: 4.797

4.  Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine.

Authors:  G V Coppa; O Gabrielli; L Zampini; F Maccari; V Mantovani; T Galeazzi; L Santoro; L Padella; R L Marchesiello; F Galeotti; N Volpi
Journal:  Metab Brain Dis       Date:  2015-05-29       Impact factor: 3.584

Review 5.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

6.  Mucopolysaccharidosis (MPS) Physical Symptom Score: Development, Reliability, and Validity.

Authors:  A Ahmed; K Rudser; A Kunin-Batson; K Delaney; C Whitley; E Shapiro
Journal:  JIMD Rep       Date:  2015-08-25

7.  Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I.

Authors:  Kelly E King; Kyle D Rudser; Igor Nestrasil; Victor Kovac; Kathleen A Delaney; Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Julie B Eisengart; Eva G Mamak; Julian Raiman; Nadia Ali; Stephanie Cagle; Paul Harmatz; Chester B Whitley; Elsa G Shapiro
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

Review 8.  Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1.

Authors:  Scott D Grosse; Wendy K K Lam; Lisa D Wiggins; Alex R Kemper
Journal:  Genet Med       Date:  2017-01-26       Impact factor: 8.822

9.  Novel frameshift variant in the IDUA gene underlies Mucopolysaccharidoses type I in a consanguineous Yemeni pedigree.

Authors:  Belal Azab; Zain Dardas; Mohannad Hamarsheh; Mohammad Alsalem; Zaid Kilani; Farah Kilani; Abdalla Awidi; Hanan Jafar; Sami Amr
Journal:  Mol Genet Metab Rep       Date:  2017-06-09

10.  A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.

Authors:  Elsa G Shapiro; Kyle Rudser; Alia Ahmed; Robert D Steiner; Kathleen A Delaney; Brianna Yund; Kelly King; Alicia Kunin-Batson; Julie Eisengart; Chester B Whitley
Journal:  Mol Genet Metab Rep       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.